NON-HODGKIN'S LYMPHOMA
Clinical trials for NON-HODGKIN'S LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new NON-HODGKIN'S LYMPHOMA trials appear
Sign up with your email to follow new studies for NON-HODGKIN'S LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental 'In-Situ' vaccine aims to train immune system against three cancers
Disease control CompletedThis early-phase trial tested a combination of four therapies to see if they could safely boost the immune system to fight cancer. 17 adults with non-Hodgkin's lymphoma, metastatic breast cancer, or head & neck cancer received low-dose radiation and two immune-boosting drugs inje…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Could less be more? new study tests shorter hospital stays after stem cell transplants
Disease control CompletedThis study looked at whether patients with multiple myeloma or non-Hodgkin lymphoma could safely skip a drug called tbo-filgrastim after a stem cell transplant and still recover quickly. The drug is normally given to boost white blood cells. The trial compared two groups: one tha…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Immunotherapy cocktail targets tough blood cancers
Disease control CompletedThis study tested the drug nivolumab (Opdivo), alone or combined with other drugs, in 320 people with relapsed or refractory non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma. The main goal was to check safety and side effects, especially for the nivolumab plus daratumu…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug may reduce transplant complications in blood cancer patients
Disease control CompletedThis study tested whether the drug palifermin could make stem cell transplants safer and reduce chronic graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. Thirty-four adults with blood cancers received palifermin before transplan…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Gut bacteria may hold key to chemo side effects
Knowledge-focused CompletedThis study looked at how chemotherapy affects the gut microbiome in 40 people with non-Hodgkin's lymphoma. Researchers collected stool samples to analyze changes in gut bacteria after treatment. The goal was to better understand why chemotherapy causes digestive problems like dia…
Matched conditions: NON-HODGKIN'S LYMPHOMA
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC